3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
47
Carboplatin
38
liposomal doxorubicin
25
Bevacizumab
23
Gemcitabine
18
Topotecan
15
pembrolizumab
14
mirvetuximab soravtansine
11
rucaparib
8
niraparib
7
Cisplatin
7
1-dodecylpyridoxal
7
trebananib
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
Nivolumab
5
cemiplimab
4
Cyclophosphamide
4
sarilumab
3
relacorilant
3
pazopanib
3
oregovomab
3
olaparib
3
Doxorubicin
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
tocilizumab
2
seribantumab
2
phenoxodiol
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fallopian Tube Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts